Per S. Sorensen-Soelberg

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine.

Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine.

Journal: Neurology and therapy

Published: October 11, 2024

Assessing disease progression and treatment response in progressive multiple sclerosis.

Assessing disease progression and treatment response in progressive multiple sclerosis.

Journal: Nature reviews. Neurology

Published: July 30, 2024

Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.

Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.

Journal: Multiple sclerosis and related disorders

Published: December 06, 2023

Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.

Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.

Journal: Multiple sclerosis and related disorders

Published: November 16, 2022

Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Journal: CNS drugs

Published: July 25, 2022

Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Journal: CNS drugs

Published: April 04, 2022

Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.

Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.

Journal: CNS drugs

Published: December 21, 2021

Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.

Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.

Journal: Multiple sclerosis and related disorders

Published: January 08, 2021

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 05, 2021

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network.

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network.

Journal: Frontiers in neurology

Published: December 30, 2020

Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.

Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.

Journal: CNS drugs

Published: January 30, 2020

Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.

Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 14, 2019

Showing 1-12 of 64

Last Updated: 09/26/2026